55 related articles for article (PubMed ID: 17601575)
1. The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer.
Seya T; Matsumoto M
Cancer Immunol Immunother; 2009 Aug; 58(8):1175-84. PubMed ID: 19184005
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.
Schreibelt G; Tel J; Sliepen KH; Benitez-Ribas D; Figdor CG; Adema GJ; de Vries IJ
Cancer Immunol Immunother; 2010 Oct; 59(10):1573-82. PubMed ID: 20204387
[TBL] [Abstract][Full Text] [Related]
3. Pattern recognition receptors of innate immunity and their application to tumor immunotherapy.
Seya T; Shime H; Ebihara T; Oshiumi H; Matsumoto M
Cancer Sci; 2010 Feb; 101(2):313-20. PubMed ID: 20059475
[TBL] [Abstract][Full Text] [Related]
4. Body mass index-dependent immunological profile changes after left ventricular assist device implantation.
Klaeske K; Messer EK; Klein S; Sieg F; Eifert S; Haunschild J; Jawad K; Saeed D; Dashkevich A; Borger MA; Dieterlen MT
Front Immunol; 2023; 14():1256725. PubMed ID: 37885885
[TBL] [Abstract][Full Text] [Related]
5. Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell-based immunotherapy.
Wijesekera DPH; Yuba E; De Silva NH; Watanabe SI; Tsukamoto M; Ichida C; Izawa T; Itoh K; Kanegi R; Hatoya S; Yamate J; Inaba T; Sugiura K
FASEB Bioadv; 2020 Jan; 2(1):5-17. PubMed ID: 32123853
[TBL] [Abstract][Full Text] [Related]
6. Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand.
De Silva NH; Akazawa T; Wijewardana V; Inoue N; Oyamada M; Ohta A; Tachibana Y; Wijesekera DPH; Kuwamura M; Nishizawa Y; Itoh K; Izawa T; Hatoya S; Hasegawa T; Yamate J; Inaba T; Sugiura K
PLoS One; 2017; 12(11):e0188738. PubMed ID: 29190690
[TBL] [Abstract][Full Text] [Related]
7. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
8. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.
Escors D
New J Sci; 2014 Jan; 2014():. PubMed ID: 24634791
[TBL] [Abstract][Full Text] [Related]
9. Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
Escors D; Liechtenstein T; Perez-Janices N; Schwarze J; Dufait I; Goyvaerts C; Lanna A; Arce F; Blanco-Luquin I; Kochan G; Guerrero-Setas D; Breckpot K
Oncoimmunology; 2013 Oct; 2(10):e26148. PubMed ID: 24244902
[TBL] [Abstract][Full Text] [Related]
10. Lentiviral vectors for cancer immunotherapy and clinical applications.
Liechtenstein T; Perez-Janices N; Escors D
Cancers (Basel); 2013 Sep; 5(3):815-37. PubMed ID: 24078865
[TBL] [Abstract][Full Text] [Related]
11. Targeting lentiviral vectors for cancer immunotherapy.
Arce F; Breckpot K; Collins M; Escors D
Curr Cancer Ther Rev; 2011 Nov; 7(4):248-260. PubMed ID: 22983382
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.
Shime H; Matsumoto M; Oshiumi H; Tanaka S; Nakane A; Iwakura Y; Tahara H; Inoue N; Seya T
Proc Natl Acad Sci U S A; 2012 Feb; 109(6):2066-71. PubMed ID: 22308357
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effects of aerobic training in obesity.
Nickel T; Hanssen H; Emslander I; Drexel V; Hertel G; Schmidt-Trucksäss A; Summo C; Sisic Z; Lambert M; Hoster E; Halle M; Weis M
Mediators Inflamm; 2011; 2011():308965. PubMed ID: 21461352
[TBL] [Abstract][Full Text] [Related]
14. Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation.
Ebihara T; Azuma M; Oshiumi H; Kasamatsu J; Iwabuchi K; Matsumoto K; Saito H; Taniguchi T; Matsumoto M; Seya T
J Exp Med; 2010 Nov; 207(12):2675-87. PubMed ID: 21059856
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral vectors in gene therapy: their current status and future potential.
Escors D; Breckpot K
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):107-19. PubMed ID: 20143172
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.
Breckpot K; Escors D
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):328-43. PubMed ID: 19857199
[TBL] [Abstract][Full Text] [Related]
17. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors.
Akazawa T; Shingai M; Sasai M; Ebihara T; Inoue N; Matsumoto M; Seya T
FEBS Lett; 2007 Jul; 581(18):3334-40. PubMed ID: 17601575
[TBL] [Abstract][Full Text] [Related]
18. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells.
Akazawa T; Ebihara T; Okuno M; Okuda Y; Shingai M; Tsujimura K; Takahashi T; Ikawa M; Okabe M; Inoue N; Okamoto-Tanaka M; Ishizaki H; Miyoshi J; Matsumoto M; Seya T
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):252-7. PubMed ID: 17190817
[TBL] [Abstract][Full Text] [Related]
19. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I.
Miyazaki M; Kanto T; Inoue M; Itose I; Miyatake H; Sakakibara M; Yakushijin T; Kakita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
J Med Virol; 2008 Jun; 80(6):980-8. PubMed ID: 18428149
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
